Axendia, Inc., a life sciences analyst firm, conducted a market research study - “The State of Generative AI in Life Sciences: The Good, The Bad, The Ugly”, presented by TetraScience, with over 200 life science professionals exploring the current landscape, opportunities, challenges, and uses cases for Gen AI applications in life sciences.
The report highlights that:
- Gen AI is a tool, not a strategy.
- Gen AI will revolutionize life sciences processes including drug discovery, R&D, and manufacturing.
- The main drivers for implementing Gen AI are increased process efficiencies, enhanced customer experience, and quality improvements.
- Life science companies are only moderately prepared for Gen AI.
Read the full report to learn more about the current view of Gen AI in drug discovery and manufacturing, medical device R&D and manufacturing, supply chain, quality, and laboratory operations.
